TransCode Therapeutics Inc (NASDAQ:RNAZ) traded at $0.54 at close of the session on Tuesday, April 01 and made an upward move of 9.27% on its previous day’s price.
Looking at the stock we see that its previous close was $0.50 and the beta (5Y monthly) reads 1.153 with the day’s price range being $0.4703 – $0.61. In terms of its 52-week price range, RNAZ has a high of $66.33 and a low of $0.43. The company’s stock has lost about -71.83% over that past 30 days.
TransCode Therapeutics Inc has a market cap of $12.62 million and is expected to release its quarterly earnings report on 2024-Nov-13.
On the other hand, looking at the outlook for the RNAZ stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell.
Looking further, we note the current price level is -41.16% off its SMA20 and -88.62% from its 50-day simple moving average. The RSI (14) is pointing at 28.62 while the volatility over the past week is 25.57% and jumps to 23.75% over the past one month. The beta value is 1.52, while the average true range (ATR) is currently pointing at 0.53.
Coming back to TransCode Therapeutics Inc (NASDAQ:RNAZ), we note that the average 3-month trading volume was 7.18 million, while that of the preceding 10-day period stands at 28.76 million. Current shares outstanding are 23.34 million.
The insiders hold 10.11% of the company’s shares while institutions hold 0.78%. The data shows that short shares as of 2025-03-14, stood at 0.34 million at a short ratio of 0.15. This represents a 4880.00 short interest in shares outstanding on 2025-03-14. Shares short rose in March from the previous month at 0.16 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -83.95% down in year-to-date price movement.
